Origin |
This transgenic strain was established by CLEA Japan, Inc. The construct is as follows: CAG promoter, loxP sequence, neomycin resistance gene, loxP sequence and Ha-ras*G12V (HrasV12). It was injected into Jcl:SD embryos (Ueda, 2006). (Oct 30, 2009) |
References |
Nohmi T, Masumura K, Toyoda-Hokaiwado N. Transgenic rat models for mutagenesis and carcinogenesis. Genes Environ. 2017 Feb 1;39:11.
Yabushita S, Fukamachi K, Kikuchi F, Ozaki M, Miyata K, Sukata T, Deguchi Y, Tanaka H, Kakehashi A, Kawamura S, Uwagawa S, Wanibuchi H, Suzui M, Alexander DB, Tsuda H. Twenty-One Proteins Up-Regulated in Human H-ras Oncogene Transgenic Rat Pancreas Cancers are Up-Regulated in Human Pancreas Cancer. Pancreas. 2013 Aug;42(6):1034-9.
Ueda S, Fukamachi K, Matsuoka Y, Takasuka N, Takeshita F, Naito A, Iigo M, Alexander DB, Moore MA, Saito I, Ochiya T, Tsuda H. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis. 2006 Dec;27(12):2497-510. |